Insilico Medicine Announces Strategic Collaboration with EQRx

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced it has entered into a strategic collaboration with EQRx, a company committed to developing and delivering innovative medicines to patients at radically lower prices.

The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise. EQRx and Insilico will engage in a co-development partnership whereby each party will be eligible for a profit share proportional to its respective level of investment.

"Both EQRx and Insilico Medicine strive to accelerate the discovery and development of new medicines and make effective therapeutics more accessible and affordable. This partnership will combine our end-to-end AI-powered drug discovery capabilities with EQRx's innovative partnership model and expertise in clinical development and patient access to accelerate the discovery and development of innovative therapies" said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.

"We are pleased to partner with Insilico Medicine, a leader in AI-based drug discovery," said Carlos Garcia-Echeverria, PhD, chief of Rx Creation at EQRx. "This collaboration will further expand our early-stage R&D efforts to fuel potential pipeline growth as we continue to apply the best of today's innovation in biomedical sciences and digital solutions to discover high-quality, innovative and more affordable medicines."